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Abstract
The blood vessels of cancerous tumours are leaky1–3 and poorly organized4–7. This can increase
the interstitial fluid pressure (IFP) inside tumours and reduce blood supply to them, which impairs
drug delivery8–9. Anti-angiogenic therapies – which “normalize” the abnormal blood vessels in
tumours by making them less leaky – have been shown to improve the delivery and effectiveness
of chemotherapeutics with low molecular-weights10, but it remains unclear whether normalizing
tumour vessels can improve the delivery of nanomedicines. Here we show that repairing the
abnormal vessels in mammary tumours, by blocking vascular endothelial growth factor (VEGF)
receptor-2, improves the delivery of small nanoparticles (12nm diameter) while hindering the
delivery of large nanoparticles (125nm diameter). We utilize a mathematical model to show that
reducing vessel wall pore sizes through normalization decreases IFP in tumours, allowing small
nanoparticles to enter them more rapidly. However, increased steric and hydrodynamic
hindrances, also associated with smaller pores, make it more difficult for large nanoparticles to
enter tumours. Our results further suggest that smaller (~12nm) nanomedicines are ideal for cancer
therapy, owing to superior tumour penetration.
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Elevated tumour IFP hinders drug delivery by abolishing fluid pressure gradients that
produce rapid convective (flow-driven) penetration into tumours11. This limits drug
penetration across vessel walls into tumours (transvascular) and through tumour tissue
(interstitial) to slow diffusion8. Anti-angiogenic therapies can repair tumour vessel
abnormalities, such as large heterogeneous pores that facilitate leakiness, by inducing vessel
maturation12–13. This “vascular normalization” reduces IFP to induce convective penetration
of molecules up to the size (~11nm) of immunoglobulin-G (IgG) (Supplementary Tables 1
and 2)12–14. Through normalization, anti-angiogenic therapies seem to benefit patients with
colorectal15 and brain tumours16–17, potentially through improved drug delivery, reduced
chemoresistance, and immune reprogramming10. Whether normalizing vessels can improve
the delivery of nanomedicines – ranging in size from 10–125nm – is not known. These
slow-diffusing large therapeutics provide new hope for cancer treatment18–19 and would
greatly benefit from convective delivery. Unfortunately, increased hydrodynamic and steric
hindrance, from smaller vessel pores caused by normalization, may compromise the
advantage from enhanced convection.
To determine how vascular normalization affects nanomedicine delivery, we studied
whether the anti-VEGF-receptor-2 antibody DC101 modulates nanoparticle penetration rates
in orthotopic mammary tumours in vivo. We used intravital multiphoton microscopy and a
system of quantum dot-based nanoparticles with tunable size and fluorescence emission
wavelength but identical surface chemistry as probes20. With these tools, we measured the
effects of DC101 on real-time delivery for particles of 12–125nm – the size range of
approved nanomedicines. Using the resulting data, we applied a novel physiologically-based
mathematical model for drug delivery to tumours to determine how anti-angiogenics affect
pore size distributions. Furthermore, we utilized this model to study how pore size
distributions can be therapeutically modulated to optimize delivery of different sizes of
nanomedicines.
We found that a 5mg/kg dose of DC101 transiently decreases vessel diameter in orthotopic
E0771 tumours – consistent with the structural vascular normalization “window” measured
in mice12–13 and patients16 (Supplementary Fig. 1). We imaged nanoparticle delivery with
or without DC101 in orthotopic 4T1 and E0771 mammary tumours (Fig. 1a, Supplementary
Fig. 2). We quantified nanoparticle penetration rates as transvascular mass flux per unit
vascular surface area and transvascular concentration difference, often termed the effective
permeability21. Vascular normalization with 10mg/kg DC101 led to a 3.1-fold enhancement
of transvascular flux in 4T1 tumours for the smallest (12nm) nanoparticles, with no
improvement in penetration for the larger (60nm and 125nm) nanoparticles (Fig. 1b).
Similarly, 5mg/kg DC101 led to 2.7-fold improvement in transvascular flux in E0771
tumours for the 12nm particles with no enhancement for the larger nanoparticles (Fig. 1c).
Some individual control tumours exhibited zero or near-zero penetration rates for the larger
nanoparticles, with DC101 therapy apparently shutting down large nanoparticle delivery in
several tumours (Fig 1b,c). Consistent with the structural normalization “window,” we
characterized a functional normalization “window” for nanoparticle delivery. During
treatment of mice bearing E0771 tumours with 5mg/kg DC101 every 3 days, the
transvascular flux of 12nm particles was enhanced on days 2 and 5 but returned to baseline
levels by day 8 (Fig. 2). Importantly, a 10mg/kg dose seemed to hinder nanoparticle delivery
in E0771 tumours (Supplementary Fig. 3), suggesting a need for judicious dosing based on
vascular sensitivity in each tumour and host.
To study how changes in vascular pore size distribution can bring about this complex size-
dependent improvement in nanoparticle penetration rates, we developed a mathematical
model of drug delivery to tumours (details in the Supplementary Information). The tumour
vasculature is represented by a two-dimensional percolation network with one inlet and one
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outlet, which has been shown to resemble the vascular structure and function of tumours
(Fig. 3a)6, 22. It involves a series of interconnected nodes representing vessel segments. Each
node is assigned a pore size, assuming a unimodal pore size distribution throughout the
tumour vasculature based on previous studies1, 23. We assume axial Poiseuille-type blood
flow24–25. Drug exchange with the interstitial space follows Starling’s approximation for
both diffusive and convective mass flux24. Interstitial drug transport also occurs by diffusion
and convection, with interstitial fluid flow driving convection calculated using Darcy’s law.
We use pore theory for the transport of spherical particles through cylindrical pores26–27 to
calculate the hindrances to diffusion and convection for each pore size24. We first solve the
steady state fluid problem requiring the net fluid accumulation at each node to be zero and
determine the microvascular pressure (MVP) and IFP (Supplementary Figs. 4–6).
Subsequently, we solve the transient drug delivery problem and calculate transvascular flux
versus particle size as in the experiment. Model parameters were based on previous studies
(Supplementary Tables 3 and 4).
Applying the model, we studied how changes in the mean and heterogeneity (standard
deviation) of the vascular pore size distribution affect fluid pressure profiles and drug
delivery in tumours. Consistent with previous studies, large heterogeneous pores result in
elevated IFP in the centre of the tumour with no transvascular pressure difference, ΔP =
MVP – IFP (Fig. 3b). Smaller, more homogenous pores produce low IFP with a non-zero
ΔP – the result of vascular normalization – that induces convection (Fig. 3b). We simulated
penetration rates for therapeutics from 1–250nm in size while varying mean pore sizes from
40–1000nm (diameter)1 for homogenous, moderate, or heterogeneous pores corresponding
to 20nm, 60nm, or 100nm pore size standard deviations respectively (area fractions held
constant; Fig. 3c). Generally, smaller therapeutics (1–12nm) demonstrate the most rapid
tumour penetration, while the largest therapeutics (125–250nm) did not appreciably leave
the vasculature (Fig. 3d). Importantly, convection is dominant at small mean pore sizes.
Increasing the mean pore size past a point (>140nm) hinders nanoscale therapeutic delivery
due to rising IFP leading to limited convection, leaving diffusion dominant (Fig. 4a). This
effect couples with increasing hydrodynamic and steric hindrance to transport as pore sizes
approach therapeutic particle size (Fig. 4b). Therefore, each size of therapeutic has its own
ideal mean pore size for maximal delivery to tumours. This ideal mean pore size becomes
larger with therapeutic size, though increasing pore size heterogeneity broadens these
maxima towards smaller mean pore sizes for therapeutics larger than 12nm.
To investigate potential translational implications of these findings, we studied whether
vascular normalization enhances the effectiveness of anti-cancer nanomedicines. We
compared two clinically-used nanomedicines with widely varied sizes – Doxil, with a
diameter of ~100nm, and Abraxane, which attains a size of ~10nm upon dilution in plasma
(Supplementary Fig. 7). Considering the 5 day normalization window we characterized for
nanoparticles, we treated mice bearing orthotopic E0771 mammary tumours with DC101
(5mg/kg) or non-specific IgG on days 0 and 3 while treating with Doxil (2mg/kg) or
Abraxane (10mg/kg) on days 1–5 (Fig. 5a). We quantified the effect of each combination
therapy based on the time to reach double the initial volume (Fig. 5b). While both Doxil and
Abraxane monotherapy induced a similar growth delay, vascular normalization with DC101
enhanced the effectiveness of only the ~10nm Abraxane while not affecting that of the
~100nm Doxil.
Combining our experimental and simulated results, several conclusions can be made. The
experiments suggest that vascular normalization with anti-angiogenic therapies will only
enhance delivery and effectiveness for relatively small therapeutics – including small-
molecule chemotherapeutics, biologics, and small nanoparticles. Together with the model,
these data support the general, yet experimentally unproven, concept that vascular
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normalization reduces vessel pore sizes (Supplementary Fig. 8). This reduces IFP leading to
a non-zero ΔP throughout tumours, an effect seen experimentally12, 15, which our model
shows can restore convective drug penetration. Unfortunately, smaller and more
homogenous pores can also hinder transport for large therapeutics, resulting in diminished or
unimproved tumour penetration for larger nanoparticles in both our experiments and
simulations. The simulations also predict that remodelling vessels to increase pore sizes
would enhance delivery for only the largest (>125nm) therapeutics, which are size-excluded
by small pores. Perhaps most importantly, they show that tumour penetration rates decrease
with increasing nanoparticle size – an effect most pronounced for tumours with smaller
vessel pores, as with normalization.
Our findings emphasize the importance of size in nanomedicine design by demonstrating
that 12nm particles penetrate tumours better than larger particles. Physical principles dictate
that both diffusive and convective penetration – transvascular and interstitial – are faster for
smaller particles8, 18, 26–27. Importantly, most normal organs feature non-sinusoid
continuous epithelium that may be either fenestrated or non-fenestrated with pore cutoff
sizes of up to 6–12nm28, suggesting that 12nm particles are the smallest that can take
advantage of the enhanced permeability and retention (EPR) effect that leads to favourable
toxicity profiles for nanomedicine19. Indeed, the smallest probe demonstrating selective
delivery – a plurality of the injected dose reaching the tumour – through passive EPR is the
~11nm IgG29. While vascular-targeted tumour-penetrating ligands can enhance nanoparticle
penetration30 and tumour cell-targeting can improve uptake and retention19, targeting
ligands cannot fully overcome tumour penetration barriers made worse by large size8.
Considering the superior mass flux into tumours and long circulation times for small
nanoparticles, along with the large number of patients receiving normalizing anti-
angiogenics5, small size may represent an important new design constraint for anti-cancer
nanomedicine.
Methods
Tumour models
Orthotopic mammary tumour models were prepared by implanting a small piece (1mm3) of
viable tumour tissue from a source tumour animal into severe combined immunodeficient
(SCID) mice bearing mammary fat pad chambers21. The tumours were allowed to grow to
3mm in diameter. All animal procedures were carried out following the Public Health
Service Policy on Humane Care of Laboratory Animals and approved by the Institutional
Animal Care and Use Committee of Massachusetts General Hospital.
Treatment
Mice were treated with 5 or 10mg/kg of DC101 (ImClone Systems), using non-specific rat
IgG for control treatments, as a 5mg/mL solution by intraperitoneal injection on days 0, 3,
and 6. Imaging studies were carried out on days 2, 5, and 8.
Nanoparticle synthesis
Nanoparticles were prepared and characterized as described previously20.
In vivo imaging
A mixture of nanoparticles with diameters of 12nm (476nm emission), 60nm (540nm
emission), and 125nm (625nm emission) was prepared for intravenous injection.
Concentrations were adjusted with in vitro calibration to result in roughly equal
photoluminescence intensity for all three nanoparticle samples under 800nm multiphoton
excitation. Following retro-orbital injection of 200µL with these concentrations, multiphoton
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imaging was carried out as described previously21 on a custom-built multiphoton laser-
scanning microscope using confocal laser-scanning microscope body (Olympus 300; Optical
Analysis Corp.) and a broadband femtosecond laser source (High Performance MaiTai,
Spectra-Physics). Image slices were taken at ~60mW at sample surface with depths from 0 –
201µm, with 2.76µm steps and 2.76×2.76µm pixels. Mosaic images were taken in raster
pattern using a motorized stage (H101, Prior Scientific, Inc.) and customized automation
software (LabView, National Instruments). Imaging studies were performed with a 20X
magnification, 0.95NA water immersion objective (Olympus XLUMPlanFl, 1-UB965,
Optical Analysis).
Image analysis
Images were analyzed using custom analysis software developed in Matlab (The
Mathworks) as described previously21. The analysis approach involved 3D vessel tracing to
create vessel metrics and a 3D map of voxel intensity versus distance to the nearest vessel
over time. Images were also corrected for sample movement over time with 3D image
registration. The normalized transvascular flux was calculated using
, where Jt is the transvascular flux, Sv is the vessel
surface area, Cv is the concentration of the probe in the vessel, C is the concentration of the
probe immediately extravascular, Peff is the effective permeability21, t is time after the initial
image, r is the distance from the vessel central axis, and R is the vessel radius at that point
along the vessel. Fluorescence intensities were used as these concentrations. The calculation
was made as an average over the entire imaged volume for each tumour.
Model equations
Details of the model and corresponding equations are provided in the Supplementary
Information section.
Tumour growth studies
E0771 mammary tumours were orthotopically implanted in female SCID mice. The mice
were split into treatment groups, time-matched for time after implantation and size-matched
for tumour volume at this time (110–111mm3). The mice were treated at this initial size with
5mg/kg DC101 or non-specific IgG on days 0 and 3 by intraperitoneal injection. The mice
were simultaneously treated with either 2mg/kg Doxil, with a diameter of ~100nm, or 10mg/
kg Abraxane, with a diameter of ~10nm, on days 1–5 by retro-orbital injection. These
relative doses are similar to the relative doses for these two nanomedicines in patients. The
primary tumours were then measured every 3 days, beginning on day 0, using callipers.
Tumour growth was quantified using the time for each to reach double its initial volume.
Statistical analysis
The data are presented as means with standard errors. Groups were compared using a
Student’s t-test, except for tumour growth data – for which we anticipated a non-normal
distribution and used an (exact) Mann-Whitney U-test. In pairwise comparisons of groups in
tumour growth experiments, P values were adjusted using Holm's method.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effects of vascular normalization on nanoparticle delivery in tumours
a, Nanoparticle penetration versus particle size in orthotopic 4T1 mammary tumours in
response to normalizing therapy with DC101. Nanoparticle concentrations – denoted by
pseudocolour – are relative to initial intravascular levels, with vessels in black.
Normalization improves 12nm particle penetration while not affecting 125nm penetration.
Scale – 100µm. b, c, Penetration rates (transvascular flux) for nanoparticles in orthotopic
4T1 and E0771 mammary tumours in mice treated with 10mg/kg or 5mg/kg DC101,
respectively. Closed symbols (top) denote averages by mouse, while open symbols (bottom)
are individual tumours. Normalization improves the transvascular flux of 12nm particles on
day 2 by a factor of 3.1 in 4T1 (P = 0.042, Student’s t-test) and 2.7 in E0771 (P = 0.049,
Student’s t-test), while not improving delivery for larger nanoparticles. Normalization also
reduces the flux of large nanoparticles to zero in several individual tumours. Animal number
n = 5 for all groups.
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Figure 2. Functional vascular normalization “window” for nanomedicine delivery
Penetration rates (transvascular flux) for 12nm nanoparticles in orthotopic E0771 mammary
tumours. Measurements over an 8 day course of treatment with either 5mg/kg DC101 or
non-specific rat IgG every 3 days starting on day 0. Closed symbols (top) denote averages
by mouse, while open symbols (bottom) are individual tumours. Treatment with DC101
enhances nanoparticle transvascular flux on days 2 (P = 0.049, Student’s t-test) and 5 (P =
0.017, Student’s t-test), with no difference in the treatment groups by day 8. Animal number
n = 4–5 for all groups.
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Figure 3. Mathematical model predictions of how changes in vascular pore size distribution
affect delivery for different sizes of drugs
a, Model tumour vasculature, formed as a percolation network, with a schematic of vessel
pore structure. b, The effect of pore size distribution on fluid pressure. Large heterogeneous
pores produce an elevated IFP that approaches the MVP, resulting in a near-zero
transvascular pressure gradient (MVP – IFP) for central tumour vessels. Small homogenous
pores result in a near-zero IFP and a high transvascular pressure gradient that can drive
convective drug delivery. c, The mean pore size (diameter) and pore size standard deviation
are varied to predict how pore size changes affect drug delivery. Three standard deviations,
at 20nm, 60nm, or 100nm, are selected to represent homogenous, moderate, and
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heterogeneous pores respectively. d, Simulations of transvascular flux versus mean pore size
and pore size standard deviation for drugs from 1–250nm in diameter.
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Figure 4. Dependence of the transvascular pressure gradient and transport hindrance on pore
size
a, Transvascular pressure difference as a function of the vessel wall pore size. The plot
presents the model predictions for three different standard deviations, namely 20, 60, and
100nm. The standard deviation of the distribution affects the transvascular pressure
difference only for small pore sizes. For pore size distributions with a mean > 400nm the
pressure difference, and thus the fluid flux across the vessel wall, is practically zero. b,
Hindrance factors for transport through pores versus particle to pore size ratio. The diffusive
(H) and convective (W) hindrance factors, which represent hydrodynamic and steric
transport hindrance through pores, depend strongly on the particle to pore size ratio (λ). A
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hindrance factor of 1 indicates no hindrance, while that of zero denotes no transport
whatsoever. Both diffusion and convection are increasingly hindered as particle size
approaches pore size.
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Figure 5. Improvement of cytotoxic nanomedicine effectiveness by vascular normalization
a, Volumes of orthotopic E0771 mammary tumours in response to treatment with DC101 or
non-specific rat IgG control (5mg/kg on days 0 and 3) in combination with either the ~10nm
nanomedicine Abraxane (10mg/kg on days 1–5) or the ~100nm nanomedicine Doxil (2mg/
kg on days 1–5). b, Quantification of tumour growth rates, based on the time to reach double
the initial volume. Abraxane (P = 0.040, Mann-Whitney U-test) and Doxil (P = 0.040,
Mann-Whitney U-test) monotherapy both induce growth delays versus the control treatment.
Normalization with DC101 enhances the effectiveness of the ~10nm Abraxane (P = 0.040,
Mann-Whitney U-test), but does not affect that of the ~100nm Doxil. Animal number n = 4–
5 for all groups.
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